SCHEMBL6426240

SCHEMBL6426240

COc1ccc(OC(F)(F)F)cc1Cn1nnc(C(=O)c2c(CO)noc2-c2ccccc2Cl)c1-c1cccnc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.38
CYP11B1 P15538 3/20 0.36
CYP11B2 P19099 3/20 0.36
F2RL3 Q96RI0 3/20 0.34
IDH1 O75874 1/20 0.34
CHRM5 P08912 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
CTSA P10619 1/20 0.32
SLC16A3 O15427 1/20 0.32
SLC16A1 P53985 1/20 0.32
MCTS1 Q9ULC4 1/20 0.32
GPBAR1 Q8TDU6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14587210 0.82 ALDH1A1 (0.46) IDH1CYP3A4CYP2D6CYP2C9SMN1; SMN2
SCHEMBL4637976 0.82 IDH1 (0.43) IDH1GPBAR1
SCHEMBL4637834 0.81 ABL1 (0.33) ABL1CYP11B1CYP11B2MAPTSMN1; SMN2
SCHEMBL4637989 0.80 ABL1 (0.47) ABL1CYP11B1CYP11B2CHRM5CYP2D6
SCHEMBL4637852 0.79 ABL1 (0.40) ABL1CYP11B1CYP11B2F2RL3IDH1
SCHEMBL4708380 0.77 IDH1 (0.42) IDH1GPBAR1
SCHEMBL4638893 0.76 ABL1 (0.44) ABL1CYP11B1CYP11B2CHRM5CYP2D6
SCHEMBL4708547 0.75 GRM2 (0.37) IDH1GPBAR1
SCHEMBL4637847 0.74 ABL1 (0.40) ABL1CYP11B1CYP11B2F2RL3IDH1
SCHEMBL4637972 0.74 ALDH1A1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 ABL1 1512/4885CYP11B1 1041/4885CYP11B2 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.